HDR monotherapy vs combination therapy in intermediate risk prostate cancer

Speakers: James Morris, MD Peter Hoskin, MD

Objectives

Discuss the pros and cons for each treatment

Pro Monotherapy: James Morris

Pro Combination therapy: Peter Hoskin

Referee: Marjory Jolicoeur

  • 15:00 - 15:10
  • May 20, 2017



curi-footer
  • © 2018 Curietherapies, tous droits reserves